PNEUMOCOCCAL VACCINES MARKET ANALYSIS

Pneumococcal Vaccines Market, By Vaccine Type (Pneumococcal Conjugate Vaccines (PCVs) (PCV13 (Prevnar 13/Prevenar 13), PCV10 (Synflorix), PCV7 (Prevnar/Prevenar)) and Pneumococcal Polysaccharide Vaccines (PPVs) (PPSV23 (Pneumovax 23), PPSV14 (Pneumo 14)), By Target Population (Adults (≥ 65 years), Children (< 5 years), High-Risk Adults (18-64 years)), By Route of Administration (Intramuscular, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Aug 2024
Code : CMI2295
Pages :150
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Pneumococcal Vaccines Market Regional Insights

To learn more about this report, request sample copy

North America is expected to dominate the pneumococcal vaccines market globally with an estimated market share of 40.3% in 2024. Being one of the early adopters of pneumococcal vaccines, the U.S. accounts for the bulk of demand. With robust healthcare expenditures and universal immunization programs for children, pneumococcal vaccination rates are quite high in the region. Major pharmaceutical companies have established strong production and distribution networks in the country to cater to the needs of the market.

Asia Pacific region is poised to be the fastest growing market for pneumococcal vaccines. While overall immunization rates are improving across most Asian countries, increasing healthcare access and spending can drive the market growth. Countries like China and India with their huge population base and growing middle class offer immense business opportunities. Many local pharmaceutical manufacturers are also actively partnering with international vaccine majors to gain approvals and supply pneumococcal vaccines in this region.

Rising awareness among parents about pneumococcal disease prevention boosts demand in Asian countries. Public as well as private healthcare providers are making concerted efforts to promote vaccination of at-risk groups. This along with supportive governmental policies bodes well for the continued growth momentum of pneumococcal vaccines market in Asia Pacific region. Rapid urbanization and economic development will further aid the Asia Pacific market's ability to emerge as a frontrunner for pneumococcal vaccine suppliers.